Free Access
Issue
Réanimation
Volume 25, Juillet 2016
Médecine interne et transversalité
Page(s) S123 - S136
Section Mise au Point / Update
DOI https://doi.org/10.1007/s13546-015-1161-4
Published online 01 March 2016
  • Vogelzang NJ, Benowitz SI, Adams S, et al (2012) Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol 30:88–109 [CrossRef] [PubMed] [Google Scholar]
  • Albini A, Pennesi G, Donatelli F, et al (2010). Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102:14–25 [Google Scholar]
  • Azoulay E, Mokart D, Pène F, et al (2013) Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium: a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol 31:2810–8 [CrossRef] [PubMed] [Google Scholar]
  • Berardi R, Caramanti M, Savini A, et al (2013) State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. Crit Rev Oncol Hematol 88:75–86 [CrossRef] [PubMed] [Google Scholar]
  • Senkus E, Jassem J (2011) Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 37:300–11 [CrossRef] [PubMed] [Google Scholar]
  • Curigliano G, Mayer EL, Burstein HJ, et al (2010) Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis 53:94–104 [CrossRef] [PubMed] [Google Scholar]
  • Seidman A, Hudis C, Pierri MK, et al (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215–21 [CrossRef] [PubMed] [Google Scholar]
  • Wu MY, Liu KS, Lin PJ, et al (2009) Resuscitation of acute anthracycline-induced cardiogenic shock and refractory hypoxemia with mechanical circulatory supports: pitfalls and strategies. Resuscitation 80:385–6 [Google Scholar]
  • Yeh ETH, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:2231–47 [Google Scholar]
  • Isner JM, Ferrans VJ, Cohen SR, et al (1983) Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. Am J Cardiol 51:1167–74 [CrossRef] [PubMed] [Google Scholar]
  • Elliott P (2006) Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 33:S2–S7 [CrossRef] [PubMed] [Google Scholar]
  • Mackay B, Ewer MS, Carrasco CH, Benjamin RS (1994) Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol 18:203–11 [CrossRef] [PubMed] [Google Scholar]
  • Ali MK, Ewer MS, Gibbs HR, et al (1994) Late doxorubicin-associated cardiotoxicity in children. The possible role of intercurrent viral infection. Cancer 74:182–8 [CrossRef] [PubMed] [Google Scholar]
  • Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23:2900–2 [CrossRef] [PubMed] [Google Scholar]
  • Ewer MS, Vooletich MT, Durand J-B, et al (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23:7820–6 [CrossRef] [PubMed] [Google Scholar]
  • Von Hoff DD, Layard MW, Basa P, et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–7 [CrossRef] [PubMed] [Google Scholar]
  • Wouters KA, Kremer LCM, Miller TL, et al (2005) Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131:561–78 [CrossRef] [PubMed] [Google Scholar]
  • Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–79 [CrossRef] [PubMed] [Google Scholar]
  • Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22:263–302 [CrossRef] [PubMed] [Google Scholar]
  • Altena R, Perik PJ, van Veldhuisen DJ, et al (2009) Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 10:391–9 [CrossRef] [PubMed] [Google Scholar]
  • Braverman AC, Antin JH, Plappert MT, et al (1991) Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 9:1215–23 [PubMed] [Google Scholar]
  • Kupari M, Volin L, Suokas A, et al (1990) Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant 5:91–8 [PubMed] [Google Scholar]
  • Gharib MI, Burnett AK (2002) Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 4:235–42 [CrossRef] [PubMed] [Google Scholar]
  • Guarneri V, Lenihan DJ, Valero V, et al (2006) Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 24:4107–15 [CrossRef] [PubMed] [Google Scholar]
  • Wadhwa D, Fallah-Rad N, Grenier D, et al (2009) Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat 117:357–64 [CrossRef] [PubMed] [Google Scholar]
  • Chen MH, Kerkelä R, Force T (2008) Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 118:84–95 [CrossRef] [PubMed] [Google Scholar]
  • Kerkelä R, Grazette L, Yacobi R, et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908–16 [CrossRef] [PubMed] [Google Scholar]
  • Chu TF, Rupnick MA, Kerkela R, et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet Lond Engl 370:2011–9 [CrossRef] [PubMed] [Google Scholar]
  • Perez EA, Koehler M, Byrne J, et al (2008) Cardiac safety of lapatinib: pooled analysis of 3,689 patients enrolled in clinical trials. Mayo Clin Proc 83:679–86 [CrossRef] [PubMed] [Google Scholar]
  • de Forni M, Malet-Martino MC, Jaillais P, et al (1992) Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 10:1795–1801 [PubMed] [Google Scholar]
  • Jensen SA, Sørensen JB (2006) Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 58:487–93 [CrossRef] [PubMed] [Google Scholar]
  • Meyer CC, Calis KA, Burke LB, et al (1997) Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 17:729–36 [PubMed] [Google Scholar]
  • Lejonc JL, Vernant JP, Macquin J, Castaigne A (1980) Myocardial infarction following vinblastine treatment. Lancet Lond Engl 2:692 [CrossRef] [Google Scholar]
  • Rowinsky EK, McGuire WP, Guarnieri T, et al (1991) Cardiac disturbances during the administration of taxol. J Clin Oncol 9:1704–12 [PubMed] [Google Scholar]
  • Meinardi MT, Gietema JA, van der Graaf WT, et al (2000) Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18:1725–32 [PubMed] [Google Scholar]
  • Escudier B, Eisen T, Stadler WM, et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–34 [CrossRef] [PubMed] [Google Scholar]
  • Quezado ZM, Wilson WH, Cunnion RE, et al (1993) High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 118:31–6 [CrossRef] [PubMed] [Google Scholar]
  • Ng M, Cunningham D, Norman AR (2005) The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 41:1542–6 [CrossRef] [PubMed] [Google Scholar]
  • Guzzetti S, Costantino G, Fundarò C (2002) Systemic inflammation, atrial fibrillation, and cancer. Circulation 106:e40 [CrossRef] [PubMed] [Google Scholar]
  • van der Hooft CS, Heeringa J, van Herpen G, et al (2004) Drug-induced atrial fibrillation. J Am Coll Cardiol 44:2117–24 [CrossRef] [PubMed] [Google Scholar]
  • Rowinsky EK, Eisenhauer EA, Chaudhry V, et al (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1–15 [Google Scholar]
  • Arbuck SG, Strauss H, Rowinsky E, et al (1993) A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr 15:117–130 [PubMed] [Google Scholar]
  • Clark TE, Edom N, Larson J, Lindsey LJ (2001) Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Saf 24:87–117 [CrossRef] [PubMed] [Google Scholar]
  • Kaur A, Yu SS, Lee AJ, Chiao TB (2003) Thalidomide-induced sinus bradycardia. Ann Pharmacother 37:1040–3 [CrossRef] [PubMed] [Google Scholar]
  • Yusuf SW, Razeghi P, Yeh ETH (2008) The diagnosis and management of cardiovascular disease in cancer patients. Curr Probl Cardiol 33:163–96 [CrossRef] [PubMed] [Google Scholar]
  • Kantarjian H, Sawyers C, Hochhaus A, et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645–52 [CrossRef] [PubMed] [Google Scholar]
  • Blom JW, Doggen CJM, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715–22 [CrossRef] [PubMed] [Google Scholar]
  • Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846–50 [CrossRef] [PubMed] [Google Scholar]
  • Sack GH, Levin J, Bell WR (1977) Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 56:1–37 [CrossRef] [PubMed] [Google Scholar]
  • Sutherland DE, Weitz IC, Liebman HA (2003) Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 72:43–52 [CrossRef] [PubMed] [Google Scholar]
  • Kakkar AK, Williamson RC (1999) Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost 25:239–43 [CrossRef] [PubMed] [Google Scholar]
  • Thompson CM, Rodgers LR (1952) Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism. Am J Med Sci 223:469–78 [CrossRef] [PubMed] [Google Scholar]
  • Levine MN, Gent M, Hirsh J, et al (1988) The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 318:404–7 [CrossRef] [PubMed] [Google Scholar]
  • Heit JA, Silverstein MD, Mohr DN, et al (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160:809–15 [CrossRef] [PubMed] [Google Scholar]
  • Mitchell L, Hoogendoorn H, Giles AR, et al (1994) Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in l’asparaginase-induced antithrombin III deficiency. Blood 83:386–391 [PubMed] [Google Scholar]
  • Pritchard KI, Paterson AH, Fine S, et al (1997) Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. J Clin Oncol 15:2302–11 [PubMed] [Google Scholar]
  • Hernandez RK, Sørensen HT, Pedersen L, et al (2009) Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer 115:4442–9 [CrossRef] [PubMed] [Google Scholar]
  • Kuenen BC, Levi M, Meijers JCM, et al (2003) Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol 21:2192–8 [CrossRef] [PubMed] [Google Scholar]
  • Nalluri SR, Chu D, Keresztes R, et al (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:2277–85 [CrossRef] [PubMed] [Google Scholar]
  • Ryberg M (2013) Cardiovascular toxicities of biological therapies. Semin Oncol 40:168–77 [CrossRef] [PubMed] [Google Scholar]
  • Rajkumar SV, Blood E, Vesole D, et al (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431–6 [CrossRef] [PubMed] [Google Scholar]
  • Palumbo A, Rajkumar SV, Dimopoulos MA, et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22:414–23 [CrossRef] [PubMed] [Google Scholar]
  • Goyal G, Bhatt VR (2015) L-asparaginase and venous thromboembolism in acute lymphocytic leukemia. Future Oncol 11:2459–70 [CrossRef] [PubMed] [Google Scholar]
  • Svendsen E, Karwinski B (1989) Prevalence of pulmonary embolism at necropsy in patients with cancer. J Clin Pathol 42:805–9 [CrossRef] [PubMed] [Google Scholar]
  • Valade S, Lemiale V, Roux A, et al (2015) Life-threatening complications and outcomes in patients with malignancies and severe pulmonary embolism. Thromb Res 135:610–5 [CrossRef] [PubMed] [Google Scholar]
  • Farge D, Debourdeau P, Beckers M, et al (2013) International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 11:56–70 [CrossRef] [PubMed] [Google Scholar]
  • Dahut WL, Gulley JL, Arlen PM, et al (2004) Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22:2532–9 [CrossRef] [PubMed] [Google Scholar]
  • Zangari M, Fink LM, Elice F, et al (2009) Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 27:4865–73 [CrossRef] [PubMed] [Google Scholar]
  • Scappaticci FA, Skillings JR, Holden SN, et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232–9 [CrossRef] [PubMed] [Google Scholar]
  • Macedo LT, da Costa Lima AB, Sasse AD (2012) Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer 12:89 [CrossRef] [PubMed] [Google Scholar]
  • Lechner K, Obermeier HL (2012) Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore) 91:195–205 [CrossRef] [PubMed] [Google Scholar]
  • Blake-Haskins JA, Lechleider RJ, Kreitman RJ (2011) Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res 17:5858–66 [CrossRef] [PubMed] [Google Scholar]
  • Zuber J, Martinez F, Droz D, et al (2002) Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature. Medicine (Baltimore) 81:321–331 [CrossRef] [PubMed] [Google Scholar]
  • Ponticelli C, Banfi G (2006) Thrombotic microangiopathy after kidney transplantation. Am J Transplant 19:789–94 [Google Scholar]
  • Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788–95 [CrossRef] [PubMed] [Google Scholar]
  • Kabbinavar FF, Schulz J, McCleod M, et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697–705 [CrossRef] [PubMed] [Google Scholar]
  • Rixe O, Billemont B, Izzedine H (2007) Hypertension as a predictive factor of Sunitinib activity. Ann Oncol 18:1117 [CrossRef] [PubMed] [Google Scholar]
  • Wu S, Chen JJ, Kudelka A, et al (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9:117–23 [CrossRef] [PubMed] [Google Scholar]
  • Wadei HM, Textor SC (2010) Hypertension in the kidney transplant recipient. Transplant Rev 24:105–20 [CrossRef] [PubMed] [Google Scholar]
  • Hoorn EJ, Walsh SB, McCormick JA, et al (2012) Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol 25:269–75 [CrossRef] [PubMed] [Google Scholar]
  • Sambasivan K, Mahmoud S, Kokache A, et al (2014) Hypersensitivity reactions to etoposide phosphate. J Oncol Pharm Pract 20:158–60 [CrossRef] [PubMed] [Google Scholar]
  • Yeh ETH (2006) Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med 57:485–98 [CrossRef] [PubMed] [Google Scholar]
  • Schimmel KJM, Richel DJ, van den Brink RBA, Guchelaar HJ (2004) Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 30:181–91 [CrossRef] [PubMed] [Google Scholar]
  • Floyd JD, Nguyen DT, Lobins RL, et al (2005) Cardiotoxicity of cancer therapy. J Clin Oncol 23:7685–96 [CrossRef] [PubMed] [Google Scholar]
  • Slørdal L, Spigset O (2006) Heart failure induced by non-cardiac drugs. Drug Saf 29:567–86 [CrossRef] [PubMed] [Google Scholar]
  • Wohlfarth P, Staudinger T, Sperr WR, et al (2014) Prognostic factors, long-term survival, and outcome of cancer patients receiving chemotherapy in the intensive care unit. Ann Hematol 93:1629–36 [CrossRef] [PubMed] [Google Scholar]
  • Song JU, Suh GY, Chung MP, et al (2011) Risk factors to predict outcome in critically ill cancer patients receiving chemotherapy in the intensive care unit. Support Care Cancer 19:491–5 [CrossRef] [PubMed] [Google Scholar]
  • Darmon M, Thiery G, Ciroldi M, et al (2005) Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy. Crit Care Med 33:2488–93 [CrossRef] [PubMed] [Google Scholar]
  • Collins C, Weiden PL (1987) Cardiotoxicity of 5-fluorouracil. Cancer Treat Rep 71:733–6 [PubMed] [Google Scholar]
  • Tallaj JA, Franco V, Rayburn BK, et al (2005) Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant 24:2196–201 [CrossRef] [PubMed] [Google Scholar]
  • Prandoni P, Falanga A, Piccioli A (2005) Cancer and venous thromboembolism. Lancet Oncol 6:401–10 [CrossRef] [PubMed] [Google Scholar]
  • Maitland ML, Bakris GL, Black HR, et al (2010) Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102:596–604 [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.